CORC

浏览/检索结果: 共5条,第1-5条 帮助

限定条件                
已选(0)清除 条数/页:   排序方式:
HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study 期刊论文
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2018, 卷号: 6, 期号: 1
作者:  Hu, Peng;  Shang, Jia;  Zhang, Wenhong;  Gong, Guozhong;  Li, Yongguo
收藏  |  浏览/下载:32/0  |  提交时间:2019/12/05
Increased and sustained HBsAg loss in HBeAg positive CHB patients switched from NUC to Peg-IFN alfa-2a: A randomised open label trial (NEW SWITCH study) 会议论文
作者:  Hu, Peng;  Dou, Xiaoguang;  Jiang, Jian-ning;  Jia, Shang;  Zhang, Wen Hong
收藏  |  浏览/下载:2/0  |  提交时间:2019/12/06
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues 期刊论文
GUT, 2016, 卷号: 65, 期号: 2
作者:  Fan, Rong;  Sun, Jian;  Yuan, Quan;  Xie, Qing;  Bai, Xuefan
收藏  |  浏览/下载:12/0  |  提交时间:2019/12/06
The 104-Week Efficacy and Safety of Telbivudine-Based Optimization Strategy in Chronic Hepatitis B Patients: A Randomized, Controlled Study 期刊论文
HEPATOLOGY, 2014, 卷号: 59, 期号: 4
作者:  Sun, Jian;  Xie, Qing;  Tan, Deming;  Ning, Qin;  Niu, Junqi
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/19
A multi-center randomized study on the efficacy and safety of switching to peginterferon alpha-2a (40KD) for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years: an interim analysis of NEW SWITCH study 会议论文
作者:  Hu, Peng;  Jia, Shang;  Zhang, Wen Hong;  Gong, Guozhong;  Li, Yongguo
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/19


©版权所有 ©2017 CSpace - Powered by CSpace